Physician

Lara Wahib Kfoury, M.D.

According to 2025 Medicare claims, Lara Kfoury, M.D. (NPI: 1700074416) practices nephrology in the Johnson City, TN market, with the plurality of this provider's patient population coming from Washington, TN. This provider's primary affiliated billing organization is EAST TENNESSEE MEDICAL ASSOCIATES, P.C. (NPI: 1619089034; TIN: 62-1017477) and primary practice location at 37604-6035.

Kfoury's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 403 traditional Medicare patients, billed 1,457 HCPCS/CPT codes, and received $133,802 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,475 prescription claims across 334 beneficiaries totaling $503,765 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 61 claims. Open Payments data shows 59 records totaling $1,223. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $251,480 and ending at $503,765. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $457 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	249	1,172	$77,056
2016	407	1,790	$156,471
2017	518	1,823	$166,405
2018	489	2,396	$219,946
2019	472	2,182	$212,458
2020	463	2,020	$201,654
2021	461	1,747	$178,189
2022	380	1,505	$139,748
2023	391	1,452	$135,312
2024	403	1,457	$133,802

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	205	1,498	$251,480
2016	227	1,933	$263,968
2017	264	2,501	$335,968
2018	304	2,441	$218,649
2019	298	2,029	$395,021
2020	311	1,989	$547,002
2021	335	2,069	$237,575
2022	319	2,164	$230,452
2023	325	2,318	$382,383
2024	334	2,475	$503,765

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	12	$226
2017	N/R	N/R	N/R
2018	N/R	88	$4,642
2019	N/R	160	$5,773
2020	N/R	189	$7,249
2021	N/R	108	$4,086
2022	N/R	60	$1,858
2023	N/R	42	$1,425
2024	N/R	61	$682

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	34	92	$258
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	127	146	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	36	43	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	176	739	$59
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	145	253	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	148	5,580	$106,914
Auryxia	Ferric Citrate	31	1,194	$74,490
Xphozah	Tenapanor Hcl	15	600	$56,030
Rayaldee	Calcifediol	42	1,237	$44,294
Lokelma	Sodium Zirconium Cyclosilicate	57	1,763	$41,068

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	23	$276
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$245
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	13	$153
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	11	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,223	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lara Wahib Kfoury, M.D.?

Tedicare shows public-source Medicare data for Lara Wahib Kfoury, M.D. (NPI 1700074416), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lara Wahib Kfoury, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lara Wahib Kfoury, M.D.?

Lara Wahib Kfoury, M.D. is linked to EAST TENNESSEE MEDICAL ASSOCIATES, P.C. (billing NPI 1619089034) in the available physician profile data.

Does Lara Wahib Kfoury, M.D. have Open Payments data?

Lara Wahib Kfoury, M.D. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.